Blood clotting study for immune skin diseases
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This study looks at how immune-related skin diseases like bullous pemphigoid and lupus affect blood clotting. The results could help doctors better understand and manage clotting risks in these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have an immune-related skin disease such as bullous pemphigoid, pemphigus, mucous membrane pemphigoid, lupus of the skin, or dermatomyositis, OR you are a healthy volunteer without these conditions.
- You must be under the care of one of the study doctors if you have the skin disease.
- You cannot have taken certain blood thinners (P2Y12 inhibitors) in the last 4 weeks.
- You cannot have had a major surgery or serious injury like a broken bone in the last 4 weeks.
- You must not have a history of internal cancer or suspected active internal cancer, though early skin cancers are okay.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects skin samples and medical information from people with skin conditions caused by their immune system. It helps researchers better understand these diseases and develop new treatments.
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
This study is for adults with certain autoimmune blistering skin conditions. Researchers want to better understand and test treatments that could improve symptoms and healing for people with these specific diseases.
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
This study looks at how a specific immune system protein (IL-17) affects inflammation in a blistering skin disease called Bullous Pemphigoid. It aims to better understand the disease to help develop future treatments.
This trial collects clinical and lab information (like blood and medical history) from people with rare autoimmune diseases, especially when symptoms are unusual. It aims to better understand what causes these illnesses and how newer treatments may help.
Hear when a new Autoimmune Bullous Dermatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.